{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T02:57:50Z","timestamp":1775357870996,"version":"3.50.1"},"reference-count":83,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100001219","name":"Lymphoma Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001219","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bprch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.beha.2016.08.001","type":"journal-article","created":{"date-parts":[[2016,8,12]],"date-time":"2016-08-12T01:54:21Z","timestamp":1470966861000},"page":"54-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Current state of hematopoietic cell transplantation in CLL as smart therapies emerge"],"prefix":"10.1016","volume":"29","author":[{"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"El-Asmar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farrukh T.","family":"Awan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-510X","authenticated-orcid":false,"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2016.08.001_bib1","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.08.001_bib2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature10113","article-title":"Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia","volume":"475","author":"Puente","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.beha.2016.08.001_bib3","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2403294","article-title":"High expression of activation-induced cytidine deaminase (AID) mRNA is associated with unmutated IGVH gene status and unfavourable cytogenetic aberrations in patients with chronic lymphocytic leukaemia","volume":"18","author":"Heintel","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.08.001_bib4","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1056\/NEJMoa023143","article-title":"ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia","volume":"348","author":"Crespo","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.08.001_bib5","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.08.001_bib6","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.08.001_bib7","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.08.001_bib8","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1200\/JCO.2009.25.3187","article-title":"Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia","volume":"28","author":"Wierda","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.08.001_bib9","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(14)70335-3","article-title":"Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study","volume":"15","author":"Burger","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2016.08.001_bib10","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1182\/blood.V122.21.525.525","article-title":"Ibrutinib in combination with bendamustine and rituximab is active and tolerable in patients With relapsed\/refractory CLL\/SLL: final results Of a phase 1b study","volume":"122","author":"Barrientos","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.001_bib11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.7326\/0003-4819-124-3-199602010-00005","article-title":"HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry","volume":"124","author":"Michallet","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beha.2016.08.001_bib12","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/sj.bmt.1703548","article-title":"Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia","volume":"29","author":"Doney","year":"2002","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.beha.2016.08.001_bib13","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/sj.bmt.1705130","article-title":"Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease","volume":"36","author":"Toze","year":"2005","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.beha.2016.08.001_bib14","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.leu.2402905","article-title":"Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning","volume":"17","author":"Dreger","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.08.001_bib15","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2007.15.4757","article-title":"Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"26","author":"Sorror","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.08.001_bib16","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood-2010-03-275420","article-title":"Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial","volume":"116","author":"Dreger","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.001_bib17","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1177\/107327481201900107","article-title":"Hematopoietic stem cell allografting for chronic lymphocytic leukemia: a focus on reduced-intensity conditioning regimens","volume":"19","author":"Kharfan-Dabaja","year":"2012","journal-title":"Cancer Control"},{"key":"10.1016\/j.beha.2016.08.001_bib18","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1182\/blood-2005-05-1778","article-title":"Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia","volume":"106","author":"Gribben","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.001_bib19","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1038\/bjc.1998.381","article-title":"Early stem cell transplantation for chronic lymphocytic leukaemia: a chance for cure?","volume":"77","author":"Dreger","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.beha.2016.08.001_bib20","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1365-2141.2007.06773.x","article-title":"Systematic review of high dose chemotherapy and autologous haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: what is the published evidence?","volume":"139","author":"Kharfan-Dabaja","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.08.001_bib21","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1182\/blood-2010-09-308775","article-title":"Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation","volume":"117","author":"Michallet","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.001_bib22","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/bmt.2011.117","article-title":"Autologous transplantation in CLL patients with B and C Binet stages: final results of the prospective randomized GOELAMS LLC 98 trial","volume":"47","author":"Brion","year":"2012","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.beha.2016.08.001_bib23","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/bmt.2013.214","article-title":"Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis","volume":"49","author":"Magni","year":"2014","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.beha.2016.08.001_bib24","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1182\/blood-2010-11-317073","article-title":"Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC","volume":"117","author":"Sutton","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.001_bib25","series-title":"Current uses and outcomes of hematopoietic stem cell transplantation: 2014 CIBMTR summary slides","author":"Pasquini","year":"2014"},{"key":"10.1016\/j.beha.2016.08.001_bib26","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/bmt.2015.69","article-title":"High-dose therapy and autologous hematopoietic cell transplantation as front-line consolidation in chronic lymphocytic leukemia: a systematic review","volume":"50","author":"Reljic","year":"2015","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.beha.2016.08.001_bib27","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1182\/blood-2012-11-469627","article-title":"TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial","volume":"121","author":"Dreger","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.001_bib28","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.leukres.2014.04.006","article-title":"Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia","volume":"38","author":"Chavez","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2016.08.001_bib29","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/annonc\/mdt511","article-title":"The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison","volume":"25","author":"Herth","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2016.08.001_bib30","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3109\/10428194.2014.930848","article-title":"Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis","volume":"56","author":"Poon","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2016.08.001_bib31","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/bmt.2012.71","article-title":"Comparing efficacy of reduced-toxicity allogeneic hematopoietic cell transplantation with conventional chemo-(immuno) therapy in patients with relapsed or refractory CLL: a Markov decision analysis","volume":"47","author":"Kharfan-Dabaja","year":"2012","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.beha.2016.08.001_bib32","first-page":"467","article-title":"Allogeneic bone marrow transplantation in chronic lymphocytic leukemia: report from the European Cooperative Group for bone marrow transplantation (8 cases)","volume":"30","author":"Michallet","year":"1988","journal-title":"Nouv Rev Fr Hematol"},{"key":"10.1016\/j.beha.2016.08.001_bib33","doi-asserted-by":"crossref","first-page":"5788","DOI":"10.1200\/JCO.2005.03.962","article-title":"Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research","volume":"23","author":"Pavletic","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.08.001_bib34","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/sj.bmt.1702237","article-title":"Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia","volume":"25","author":"Pavletic","year":"2000","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.beha.2016.08.001_bib35","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1200\/JCO.2005.04.531","article-title":"Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia","volume":"23","author":"Moreno","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.08.001_bib36","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/leu.2012.228","article-title":"Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome","volume":"27","author":"Brown","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.08.001_bib37","series-title":"Current use and outcome of hematopoietic stem cell transplantation:CIBMTR summary slides","first-page":"2013","author":"Pasquini","year":"2013"},{"key":"10.1016\/j.beha.2016.08.001_bib38","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.beha.2016.08.001_bib39","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2007.06591.x","article-title":"Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia","volume":"137","author":"Khouri","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.08.001_bib40","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.bbmt.2006.06.004","article-title":"Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia","volume":"12","author":"Brown","year":"2006","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.beha.2016.08.001_bib41","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.exphem.2012.10.008","article-title":"Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: long-term prospective multicenter study","volume":"41","author":"Michallet","year":"2013","journal-title":"Exp Hematol"},{"key":"10.1016\/j.beha.2016.08.001_bib42","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1200\/JCO.2008.16.2982","article-title":"Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis","volume":"26","author":"Schetelig","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.08.001_bib43","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.bbmt.2008.09.001","article-title":"The effect of in\u00a0vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia","volume":"14","author":"Delgado","year":"2008","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.beha.2016.08.001_bib44","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/bmt.2009.61","article-title":"Reduced intensity versus full myeloablative stem cell transplant for advanced CLL","volume":"44","author":"Peres","year":"2009","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.beha.2016.08.001_bib45","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/annonc\/mdp259","article-title":"Does reduced-intensity allogeneic transplantation confer a survival advantage to patients with poor prognosis chronic lymphocytic leukaemia? A case-control retrospective analysis","volume":"20","author":"Delgado","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2016.08.001_bib46","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.exphem.2013.04.015","article-title":"Rapid complete donor lymphoid chimerism and graft-versus-leukemia effect are important in early control of chronic lymphocytic leukemia","volume":"41","author":"Shaffer","year":"2013","journal-title":"Exp Hematol"},{"key":"10.1016\/j.beha.2016.08.001_bib47","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2217\/imt.14.100","article-title":"Predictors of outcome in reduced intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: summarizing the evidence and highlighting the limitations","volume":"7","author":"Kharfan-Dabaja","year":"2015","journal-title":"Immunotherapy"},{"key":"10.1016\/j.beha.2016.08.001_bib48","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood.V76.12.2462.2462","article-title":"Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients","volume":"76","author":"Kolb","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.001_bib49","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2217\/imt.13.31","article-title":"Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies","volume":"5","author":"El-Jurdi","year":"2013","journal-title":"Immunotherapy"},{"key":"10.1016\/j.beha.2016.08.001_bib50","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1182\/blood-2003-12-4321","article-title":"Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR","volume":"104","author":"Ritgen","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.001_bib51","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1182\/blood-2002-02-0506","article-title":"The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation","volume":"100","author":"Marks","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.001_bib52","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.bmt.1705074","article-title":"Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation","volume":"36","author":"Russell","year":"2005","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.beha.2016.08.001_bib53","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","article-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765","volume":"117","author":"Herman","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.001_bib54","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1182\/blood-2011-06-338855","article-title":"B-cell receptor signaling in chronic lymphocytic leukemia","volume":"118","author":"Stevenson","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.001_bib55","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nature11309","article-title":"Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling","volume":"489","author":"Duhren-von Minden","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.beha.2016.08.001_bib56","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nri2853","article-title":"The tipping points in the initiation of B cell signalling: how small changes make big differences","volume":"10","author":"Pierce","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.beha.2016.08.001_bib57","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1182\/blood-2004-07-2669","article-title":"Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells","volume":"105","author":"Petlickovski","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.001_bib58","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.4049\/jimmunol.165.3.1300","article-title":"B\u00a0cell antigen receptor-induced activation of Akt promotes B cell survival and is dependent on Syk kinase","volume":"165","author":"Pogue","year":"2000","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.beha.2016.08.001_bib59","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.cell.2009.08.041","article-title":"PI3 kinase signals BCR-dependent mature B cell survival","volume":"139","author":"Srinivasan","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.beha.2016.08.001_bib60","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-14-1889","article-title":"New strategies in chronic lymphocytic leukemia: shifting treatment paradigms","volume":"20","author":"Awan","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2016.08.001_bib61","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beha.2016.08.001_bib62","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.001_bib63","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(13)70513-8","article-title":"Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b\/2 trial","volume":"15","author":"O'Brien","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2016.08.001_bib64","first-page":"7057","article-title":"Covariation of psychological and inflammatory variables in patients with chronic lymphocytic leukemia receiving ibrutinib","volume":"32","author":"Godiwala","year":"2014","journal-title":"ASCO Meet Abstr"},{"key":"10.1016\/j.beha.2016.08.001_bib65","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1200\/JCO.2014.60.3282","article-title":"Hope for high-risk chronic lymphocytic leukemia relapsing after allogeneic stem-cell transplantation","volume":"33","author":"Montserrat","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.08.001_bib66","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/leu.2014.42","article-title":"Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center","volume":"28","author":"Stephens","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.08.001_bib67","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.08.001_bib68","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.08.001_bib69","doi-asserted-by":"crossref","first-page":"19236","DOI":"10.1074\/jbc.272.31.19236","article-title":"p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes","volume":"272","author":"Chantry","year":"1997","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.beha.2016.08.001_bib70","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","article-title":"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals","volume":"116","author":"Herman","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.001_bib71","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.08.001_bib72","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/imr.12243","article-title":"Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies","volume":"263","author":"Gill","year":"2015","journal-title":"Immunol Rev"},{"key":"10.1016\/j.beha.2016.08.001_bib73","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.beha.2016.08.001_bib74","doi-asserted-by":"crossref","first-page":"OF7","DOI":"10.1158\/2159-8290.CD-NB2014-102","article-title":"ABT-199 shows effectiveness in CLL","volume":"4","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.beha.2016.08.001_bib75","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.beha.2016.08.001_bib76","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.08.001_bib77","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/ng.1032","article-title":"Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia","volume":"44","author":"Quesada","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.beha.2016.08.001_bib78","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1200\/JOP.2014.002469","article-title":"Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels","volume":"11","author":"Shanafelt","year":"2015","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.beha.2016.08.001_bib79","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","article-title":"Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib","volume":"125","author":"Jain","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.001_bib80","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2016.08.001_bib81","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/sj.leu.2404441","article-title":"Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus","volume":"21","author":"Dreger","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.08.001_bib82","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3324\/haematol.10720","article-title":"Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival","volume":"92","author":"Stilgenbauer","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2016.08.001_bib83","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/cncr.23671","article-title":"Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia","volume":"113","author":"Kharfan-Dabaja","year":"2008","journal-title":"Cancer"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692616300032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692616300032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T03:31:37Z","timestamp":1601004697000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692616300032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S1521692616300032"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2016.08.001","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current state of hematopoietic cell transplantation in CLL as smart therapies emerge","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2016.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}